The RCC PDX model harbors RAS-pathway activation via BRAF mutations (G466A and D594N), with corresponding ERK signaling activation, which may partially explain its insensitivity to cetuximab treatment (29). This evidence concerns the gene BRAF and renal cell carcinoma.